首页> 外文期刊>International Journal of Hygiene and Environmental Health >Analysis of the variability of the pharmacokinetics of multiple drugs in young adult and elderly subjects and its implications for acceptable daily exposures and cleaning validation limits
【24h】

Analysis of the variability of the pharmacokinetics of multiple drugs in young adult and elderly subjects and its implications for acceptable daily exposures and cleaning validation limits

机译:分析多种药物在年轻人和老年人中的药代动力学的变异性及其对可接受的每日暴露量和清洁验证限值的影响

获取原文
获取原文并翻译 | 示例
           

摘要

The elderly constitute a significant, potentially sensitive, subpopulation within the general population, which must be taken into account when performing risk assessments including determining an acceptable daily exposure (ADE) for the purpose of a cleaning validation. Known differences in the pharmacokinetics of drugs between young adults (who are typically the subjects recruited into clinical trials) and the elderly are potential contributors affecting the interindividual uncertainty factor (UFH) component of the ADE calculation. The UFH values were calculated for 206 drugs for young adult and elderly groups separately and combined (with the elderly assumed to be a sensitive subpopulation) from published studies where the pharmacokinetics of the young adult and elderly groups were directly compared. Based on the analysis presented here, it is recommended to use a default UFH value of 10 for worker populations (which are assumed to be approximately equivalent to the young adult groups) where no supporting pharmacokinetic data exist, while it is recommended to use a default UFH value of 15 for the general population, to take the elderly into consideration when calculating ADE values. The underlying reasons for the large differences between the exposures in the young adult and elderly subjects for the 10 compounds which show the greatest separation are different in almost every case, involving the OCT2 transporter, glucuronidation, hydrolysis, CYP1A2, CYP2A6, CYP2C19, CYP2D6, CYP3A4 or CYP3A5. Therefore, there is no consistent underlying mechanism which appears responsible for the largest differences in pharmacokinetic parameters between young adult and elderly subjects. (C) 2017 Elsevier GmbH. All rights reserved.
机译:老年人是普通人群中重要的潜在敏感人群,在进行风险评估(包括确定可接受的每日暴露量(ADE)以进行清洁验证)时,必须将老年人考虑在内。年轻人(通常是参加临床试验的受试者)与老年人之间已知的药物药代动力学差异是影响ADE计算的个体不确定性因素(UFH)的潜在因素。 UFH值是分别针对年轻人和老年人群的206种药物计算得出的,并与已发表的研究(直接比较年轻人和老年人群的药代动力学)进行了组合(假设老年人是敏感的亚群)。根据此处介绍的分析,建议对于没有支持药代动力学数据的工人人群,使用默认UFH值10(假定大约等于年轻成年人群),而建议使用默认值对于一般人群,UFH值为15,因此在计算ADE值时要考虑到老年人。在几乎每种情况下,显示最大分离度的10种化合物在年轻人和老年人中的暴露之间存在巨大差异的根本原因在几乎每种情况下都是不同的,涉及OCT2转运蛋白,葡糖醛酸化,水解,CYP1A2,CYP2A6,CYP2C19,CYP2D6, CYP3A4或CYP3A5。因此,没有一致的潜在机制似乎是造成成年人和老年人之间药代动力学参数最大差异的原因。 (C)2017 Elsevier GmbH。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号